BIOMAT Database Logo BIOMAT Database Logo

[Effects of a new alpha- and beta-adrenoceptor blocking drug (YM-09538) on intraoperative hypertension]. 1988

K Sha, and H Furuya, and M Kuro, and K Kitaguchi, and N Yamagishi, and S Marunaka, and J Shimoyama, and T Okuda

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007431 Intraoperative Complications Complications that affect patients during surgery. They may or may not be associated with the disease for which the surgery is done, or within the same surgical procedure. Peroperative Complications,Surgical Injuries,Complication, Intraoperative,Complication, Peroperative,Injuries, Surgical,Complications, Intraoperative,Complications, Peroperative,Injury, Surgical,Intraoperative Complication,Peroperative Complication,Surgical Injury
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004983 Ethanolamines AMINO ALCOHOLS containing the ETHANOLAMINE; (-NH2CH2CHOH) group and its derivatives. Aminoethanols
D005260 Female Females
D006339 Heart Rate The number of times the HEART VENTRICLES contract per unit of time, usually per minute. Cardiac Rate,Chronotropism, Cardiac,Heart Rate Control,Heartbeat,Pulse Rate,Cardiac Chronotropy,Cardiac Chronotropism,Cardiac Rates,Chronotropy, Cardiac,Control, Heart Rate,Heart Rates,Heartbeats,Pulse Rates,Rate Control, Heart,Rate, Cardiac,Rate, Heart,Rate, Pulse
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000317 Adrenergic alpha-Antagonists Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. Adrenergic alpha-Receptor Blockaders,alpha-Adrenergic Blocking Agents,alpha-Adrenergic Receptor Blockaders,alpha-Blockers, Adrenergic,Adrenergic alpha-Blockers,alpha-Adrenergic Antagonists,alpha-Adrenergic Blockers,Adrenergic alpha Antagonists,Adrenergic alpha Blockers,Adrenergic alpha Receptor Blockaders,Agents, alpha-Adrenergic Blocking,Antagonists, alpha-Adrenergic,Blockaders, Adrenergic alpha-Receptor,Blockaders, alpha-Adrenergic Receptor,Blockers, alpha-Adrenergic,Blocking Agents, alpha-Adrenergic,Receptor Blockaders, alpha-Adrenergic,alpha Adrenergic Antagonists,alpha Adrenergic Blockers,alpha Adrenergic Blocking Agents,alpha Adrenergic Receptor Blockaders,alpha Blockers, Adrenergic,alpha-Antagonists, Adrenergic,alpha-Receptor Blockaders, Adrenergic
D000319 Adrenergic beta-Antagonists Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. Adrenergic beta-Antagonist,Adrenergic beta-Receptor Blockader,Adrenergic beta-Receptor Blockaders,beta-Adrenergic Antagonist,beta-Adrenergic Blocker,beta-Adrenergic Blocking Agent,beta-Adrenergic Blocking Agents,beta-Adrenergic Receptor Blockader,beta-Adrenergic Receptor Blockaders,beta-Adrenoceptor Antagonist,beta-Blockers, Adrenergic,beta-Adrenergic Antagonists,beta-Adrenergic Blockers,beta-Adrenoceptor Antagonists,Adrenergic beta Antagonist,Adrenergic beta Antagonists,Adrenergic beta Receptor Blockader,Adrenergic beta Receptor Blockaders,Adrenergic beta-Blockers,Agent, beta-Adrenergic Blocking,Agents, beta-Adrenergic Blocking,Antagonist, beta-Adrenergic,Antagonist, beta-Adrenoceptor,Antagonists, beta-Adrenergic,Antagonists, beta-Adrenoceptor,Blockader, Adrenergic beta-Receptor,Blockader, beta-Adrenergic Receptor,Blockaders, Adrenergic beta-Receptor,Blockaders, beta-Adrenergic Receptor,Blocker, beta-Adrenergic,Blockers, beta-Adrenergic,Blocking Agent, beta-Adrenergic,Blocking Agents, beta-Adrenergic,Receptor Blockader, beta-Adrenergic,Receptor Blockaders, beta-Adrenergic,beta Adrenergic Antagonist,beta Adrenergic Antagonists,beta Adrenergic Blocker,beta Adrenergic Blockers,beta Adrenergic Blocking Agent,beta Adrenergic Blocking Agents,beta Adrenergic Receptor Blockader,beta Adrenergic Receptor Blockaders,beta Adrenoceptor Antagonist,beta Adrenoceptor Antagonists,beta Blockers, Adrenergic,beta-Antagonist, Adrenergic,beta-Antagonists, Adrenergic,beta-Receptor Blockader, Adrenergic,beta-Receptor Blockaders, Adrenergic

Related Publications

K Sha, and H Furuya, and M Kuro, and K Kitaguchi, and N Yamagishi, and S Marunaka, and J Shimoyama, and T Okuda
Adrenoceptor blocking hemodynamic and coronary effects of YM-09538, a new combined alpha- and beta-adrenoceptor blocking drug, in anesthetized dogs.
November 1982, European journal of pharmacology,
K Sha, and H Furuya, and M Kuro, and K Kitaguchi, and N Yamagishi, and S Marunaka, and J Shimoyama, and T Okuda
Comparison of airway obstruction induced by propranolol and YM-09538 (a combined alpha- and beta-adrenoceptor blocking drug).
March 1982, Archives internationales de pharmacodynamie et de therapie,
K Sha, and H Furuya, and M Kuro, and K Kitaguchi, and N Yamagishi, and S Marunaka, and J Shimoyama, and T Okuda
[Effects of alpha-and beta-adrenoceptor blocking agent (YM-09538) upon the clinical features of a patient with pheochromocytoma].
December 1982, Horumon to rinsho. Clinical endocrinology,
K Sha, and H Furuya, and M Kuro, and K Kitaguchi, and N Yamagishi, and S Marunaka, and J Shimoyama, and T Okuda
Adrenoceptor blocking and cardiovascular effects of the optical isomers of amosulalol (YM-09538), a combined alpha- and beta-adrenoceptor blocking agent, and the corresponding desoxy derivative (YM-11133) in rats.
August 1986, Japanese journal of pharmacology,
K Sha, and H Furuya, and M Kuro, and K Kitaguchi, and N Yamagishi, and S Marunaka, and J Shimoyama, and T Okuda
Affinities for alpha- and beta-adrenoceptor subtypes of YM-09538, a new combined alpha- and beta-adrenoceptor antagonist, by radioligand binding assay.
March 1983, Archives internationales de pharmacodynamie et de therapie,
K Sha, and H Furuya, and M Kuro, and K Kitaguchi, and N Yamagishi, and S Marunaka, and J Shimoyama, and T Okuda
Cardiac effects of YM-09538, a new alpha- and beta-adrenoceptor blocking agent, on SA nodal pacemaker activity and contractility in isolated atria and intact dogs.
July 1982, Japanese heart journal,
K Sha, and H Furuya, and M Kuro, and K Kitaguchi, and N Yamagishi, and S Marunaka, and J Shimoyama, and T Okuda
Autonomic and antihypertensive activity of oral amosulalol (YM-09538), a combined alpha- and beta-adrenoceptor blocking agent in conscious rats.
May 1985, Japanese journal of pharmacology,
K Sha, and H Furuya, and M Kuro, and K Kitaguchi, and N Yamagishi, and S Marunaka, and J Shimoyama, and T Okuda
Adrenoceptor blocking properties of the stereoisomers of amosulalol (YM-09538) and the corresponding desoxy derivative (YM-11133).
March 1986, The Journal of pharmacology and experimental therapeutics,
K Sha, and H Furuya, and M Kuro, and K Kitaguchi, and N Yamagishi, and S Marunaka, and J Shimoyama, and T Okuda
Adrenoceptor blocking effects of arotinolol, a new combined alpha- and beta-adrenoceptor blocking agent.
October 1984, Archives internationales de pharmacodynamie et de therapie,
K Sha, and H Furuya, and M Kuro, and K Kitaguchi, and N Yamagishi, and S Marunaka, and J Shimoyama, and T Okuda
Determination of the alpha, beta-adrenoceptor blocker YM-09538 in urine by gas chromatography with a nitrogen-sensitive detector.
June 1983, Journal of chromatography,
Copied contents to your clipboard!